Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03321552




Registration number
NCT03321552
Ethics application status
Date submitted
30/08/2017
Date registered
25/10/2017
Date last updated
19/01/2024

Titles & IDs
Public title
PROMISE International
Scientific title
Percutaneous Deep Vein Arterialization Post-Market Study
Secondary ID [1] 0 0
EU PMS Revision 4.1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Critical Limb Ischemia 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Surgery - Percutaneous deep vein arterialization
Treatment: Devices - LimFlow System

Experimental: Percutaneous deep vein arterialization - Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach


Treatment: Surgery: Percutaneous deep vein arterialization
Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach

Treatment: Devices: LimFlow System
Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
Intervention code [1] 0 0
Treatment: Surgery
Intervention code [2] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Amputation-free survival
Timepoint [1] 0 0
Throughout one year
Secondary outcome [1] 0 0
Wound healing
Timepoint [1] 0 0
Throughout one year
Secondary outcome [2] 0 0
Primary and secondary patency as assessed by duplex ultrasound
Timepoint [2] 0 0
Throughout one year
Secondary outcome [3] 0 0
Limb salvage: Freedom from major amputation
Timepoint [3] 0 0
Throughout one year
Secondary outcome [4] 0 0
Deterioration in renal function as assessed by creatinine level
Timepoint [4] 0 0
One month and six months
Secondary outcome [5] 0 0
Technical success (procedure completion)
Timepoint [5] 0 0
Immediately post-procedure
Secondary outcome [6] 0 0
Procedural success (technical success without death, major amputation, or re-intervention)
Timepoint [6] 0 0
One month post-procedure

Eligibility
Key inclusion criteria
- Subject must be > 21 and < 95 years of age

- Clinical diagnosis of symptomatic critical limb ischemia, defined as Rutherford
category 5 or 6

- Assessment that no conventional surgical or endovascular treatment is possible

- Proximally, the target in-flow artery at the cross-over point must be treatable with a
3.5 - 4.0 mm stent after pre-treatment (by visual estimate), and be <50% stenosed

- Subject is willing and has adequate support to comply with protocol requirements,
including medication regimen and follow-up visits
Minimum age
21 Years
Maximum age
95 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Concomitant hepatic insufficiency, deep venous thrombus in target limb, uncorrected
coagulation disorders, or current immunodeficiency disorder

- Prior vein stripping surgery and/or vessel harvesting for CABG in the limb intended
for study

- Life expectancy less than 12 months

- Patient currently taking coumarin/warfarin which, in the opinion of the attending
physician, interferes with the patient's treatment

- Any significant medical condition which, in the attending physician's opinion, may
interfere with the patient's optimal treatment

- Patient currently participating in another investigational drug or device study that
has not completed the primary endpoint or that clinically interferes with the
endpoints of this treatment

- Patient unable to give consent

- Pregnant or breastfeeding women

- Documented myocardial infarction or stroke within previous 90 days

- Patients suffering from renal insufficiency (GFR value less than 30 ml/min/1.73 m²)
who are not on hemodialysis

- Patients with vasculitis and/or untreated popliteal aneurysms

- Patients with acute limb ischemia

- Prior peripheral arterial bypass procedure above or below the knee which could inhibit
proximal inflow to the stent graft

- Lower extremity venous disease with significant edema in the target limb that may
inhibit the procedure and/or jeopardize wound healing, in the investigator's opinion

- Known or suspected systemic or severe infection (e.g., WIfI foot Infection grade of 3)

- Known or suspected allergies or contraindications to stainless steel, nickel, or
contrast agent that cannot be adequately pre-treated, or patients who cannot receive
anticoagulation or antiplatelet aggregation therapy

- Severe heart failure, which in the opinion of the investigator may compromise
subject's ability to safely undergo a percutaneous procedure (e.g., known ejection
fraction of < 40%, NYHA Classification III-IV)

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
24/01/2025
Actual
Sample size
Target
Accrual to date
Final
35
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Graz
Country [2] 0 0
Germany
State/province [2] 0 0
Baden-Württemberg
Country [3] 0 0
Germany
State/province [3] 0 0
North Rhine-Westphalia
Country [4] 0 0
Germany
State/province [4] 0 0
Saxony
Country [5] 0 0
Netherlands
State/province [5] 0 0
's-Hertogenbosch
Country [6] 0 0
Netherlands
State/province [6] 0 0
Alkmaar
Country [7] 0 0
Netherlands
State/province [7] 0 0
Nieuwegein
Country [8] 0 0
New Zealand
State/province [8] 0 0
Auckland
Country [9] 0 0
Singapore
State/province [9] 0 0
Singapore

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
LimFlow SA
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this post-market study is to evaluate the safety and effectiveness of the
LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization
in subjects with critical limb ischemia.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03321552
Trial related presentations / publications
Schreve MA, Lichtenberg M, Unlu C, Branzan D, Schmidt A, van den Heuvel DAF, Blessing E, Brodmann M, Cabane V, Lin WTQ, Kum S. PROMISE international; a clinical post marketing trial investigating the percutaneous deep vein arterialization (LimFlow) in the treatment of no-option chronic limb ischemia patient. CVIR Endovasc. 2019 Jul 31;2(1):26. doi: 10.1186/s42155-019-0067-z.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries